BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Darovasertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Darovasertib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05987332-10793@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Darovasertib: Phase 2/3 readout est. (NCT05987332)
DESCRIPTION:Darovasertib\, phase 2/3\, Uveal Melanoma.\nStudy: IDE196 (Daro
 vasertib) in Combination With Crizotinib as First-line Therapy in Metastat
 ic Uveal Melanoma\nEstimated primary completion: 15 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05987332
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-10793@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Darovasertib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Darovasertib\, phase 1/2\, Uveal Melanoma.\nStudy: Study of IDE
 196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusi
 ons\nEstimated primary completion: 29 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907954-10793@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Darovasertib: Phase 2 readout est. (NCT05907954)
DESCRIPTION:Darovasertib\, phase 2\, Uveal Melanoma.\nStudy: (Neo)Adjuvant 
 IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma\nEstimate
 d primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/darovasertib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05907954
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015190-10793@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07015190)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Neoadjuvant Da
 rovasertib in Primary Uveal Melanoma\nEstimated primary completion: Octobe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/darovasertib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0701
 5190
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804186-10793@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Darovasertib: Phase 3 readout est. (NCT07804186)
DESCRIPTION:Darovasertib\, phase 3\, Uveal Melanoma.\nStudy: Study of Adjuv
 ant Darovasertib and Crizotinib in Participants With Primary Non-metastati
 c Uveal Melanoma\nEstimated primary completion: March 2034. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/darovasertib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07804186
URL:https://assetmemo.bio/drug/darovasertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
